Drugs / dihydroaremisinin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03402464 | Jan 2018 → Jun 2019 | lung adenocarcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dihydroaremisinin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03402464 ↗ |
| Known as | DHA | “icotinib/dihydroaremisinin (DHA)-based combination therapy” NCT03402464 ↗ |
| Route | Oral | “oral dihydroaremisinin was given at 20mg per day” NCT03402464 ↗ |